Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines

키워드

참고문헌 (100)

1. "Fact Sheet: Influenza (Seasonal)"[URL]
2. Hagiwara Y, "Seasonal influenza, its complications and related healthcare resource utilization among people 60 years and older : a descriptive retrospective study in Japan", PLoS One, 17, pp.e0272795~ (2022)
3. Comber L, "Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age", Rev Med Virol, 33, pp.e2330~ (2023)
4. Peteranderl C, "Human influenza virus infections", Semin Respir Crit Care Med, 37, pp.487~500 (2016)
5. Krammer F, "Influenza", Nat Rev Dis Primers, 4, pp.3~ (2018)
6. "Flu symptoms & complications"[URL]
7. Rcheulishvili N, "Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs-focus on the bigger picture", Front Immunol, 13, pp.1025884~ (2022)
8. Wang WC, "Progress towards the development of a universal influenza vaccine", Viruses, 14, pp.1684~ (2022)
9. Jazayeri SD, "Development of universal influenza vaccines targeting conserved viral proteins", Vaccines(Basel), 7, pp.169~ (2019)
10. Nachbagauer R, "Is a universal influenza virus vaccine possible?", Annu Rev Med, 71, pp.315~327 (2020)
11. Du R, "Flu universal vaccines : new tricks on an old virus", Virol Sin, 36, pp.13~24 (2021)
12. Li J, "Influenza and universal vaccine research in China", Viruses, 15, pp.116~ (2022)
13. Mezhenskaya D, "M2e-based universal influenza vaccines : a historical overview and new approaches to development", J Biomed Sci, 26, pp.76~ (2019)
14. Beans C, "Researchers getting closer to a"universal"flu vaccine", Proc Natl Acad Sci U S A, 119, pp.e2123477119~ (2022)
15. Wang Y, "Universal influenza vaccines : from viruses to nanoparticles", Expert Rev Vaccines, 17, pp.967~976 (2018)
16. Jang YH, "The quest for a truly universal influenza vaccine", Front Cell Infect Microbiol, 9, pp.344~ (2019)
17. Wiesel M, "Virus-specific CD8 T cells : activation, differentiation and memory formation", APMIS, 117, pp.356~381 (2009)
18. Prigge AD, "Age-dependent differences in T-cell responses to influenza A virus", Am J Respir Cell Mol Biol, 63, pp.415~423 (2020)
19. Heath WR, "Cross-presentation in viral immunity and self-tolerance", Nat Rev Immunol, 1, pp.126~134 (2001)
20. Gaevert JA, "Quantifying T cell cross-reactivity : influenza and coronaviruses", Viruses, 13, pp.1786~ (2021)
21. Embgenbroich M, "Current concepts of antigen cross-presentation", Front Immunol, 9, pp.1643~ (2018)
22. Hashimoto M, "CD8 T cell exhaustion in chronic infection and cancer : opportunities for interventions", Annu Rev Med, 69, pp.301~318 (2018)
23. Duan S, "Balancing immune protection and immune pathology by CD8+ T-cell responses to influenza infection", Front Immunol, 7, pp.25~ (2016)
24. Topham DJ, "Immunity to influenza infection in humans", Cold Spring Harb Perspect Med, 11, pp.a038729~ (2021)
25. Frank K, "Dynamic natural killer cell and T cell responses to influenza infection", Front Cell Infect Microbiol, 10, pp.425~ (2020)
26. Okoli GN, "Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains : a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009", 10 influenza pandemic, 2021, pp.39, 1225~1240
27. Chang D, "Why glycosylation matters in building a better flu vaccine", Mol Cell Proteomics, 18, pp.2348~2358 (2019)
28. Clemens EB, "Harnessing the power of T cells : the promising hope for a universal influenza vaccine", Vaccines(Basel), 6, pp.18~ (2018)
29. Uddbäck I, "Harnessing cross-reactive CD8+ TRM cells for long-standing protection against influenza A virus", Viral Immunol, 33, pp.201~207 (2020)
30. Assarsson E, "Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans", J Virol, 82, pp.12241~12251 (2008)
31. McGee MC, "Evolutionary conservation and positive selection of influenza A nucleoprotein CTL epitopes for universal vaccination", J Med Virol, 94, pp.2578~2587 (2022)
32. Sui Z, "Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant", Vaccine, 28, pp.7690~7698 (2010)
33. Rak A, "Nucleoprotein as a promising antigen for broadly protective influenza vaccines", Vaccines(Basel), 11, pp.1747~ (2023)
34. Uddbäck IE, "PB1 as a potential target for increasing the breadth of T-cell mediated immunity to Influenza A", Sci Rep, 6, pp.35033~ (2016)
35. van de Wall S, "Influenza-specific lung-resident memory CD8+ T cells", Cold Spring Harb Perspect Biol, 13, pp.a037978~ (2021)
36. Paik DH, "Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity", J Exp Med, 218, pp.e20200218~ (2021)
37. Brown LE, "Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes", Immunol Cell Biol, 87, pp.300~308 (2009)
38. Mbawuike IN, "Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes", Respir Res, 8, pp.44~ (2007)
39. Staneková Z, "Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development", Virol J, 7, pp.351~ (2010)
40. Pizzolla A, "Memory T cell dynamics in the lung during influenza virus infection", J Immunol, 202, pp.374~381 (2019)
41. Wu T, "Lung-resident memory CD8 T cells(TRM)are indispensable for optimal cross-protection against pulmonary virus infection", J Leukoc Biol, 95, pp.215~224 (2014)
42. Son YM, "Co-ordination of mucosal B cell and CD8 T cell memory by tissue-resident CD4 helper T cells", Cells, 10, pp.2355~ (2021)
43. Janssens Y, "The role of cell-mediated immunity against influenza and its implications for vaccine evaluation", Front Immunol, 13, pp.959379~ (2022)
44. Park SL, "Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses", Nat Immunol, 19, pp.183~191 (2018)
45. Sant AJ, "CD4 T cells in protection from influenza virus : Viral antigen specificity and functional potential", Immunol Rev, 284, pp.91~105 (2018)
46. Choi H, "CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8+ T cells", BMC Immunol, 24, pp.15~ (2023)
47. Kervevan J, "Role of CD4+ T cells in the control of viral infections : recent advances and open questions", Int J Mol Sci, 22, pp.523~ (2021)
48. Laidlaw BJ, "The multifaceted role of CD4+ T cells in CD8+ T cell memory", Nat Rev Immunol, 16, pp.102~111 (2016)
49. Cullen JG, "CD4+ T help promotes influenza virus-specific CD8+ T cell memory by limiting metabolic dysfunction", Proc Natl Acad Sci U S A, 116, pp.4481~4488 (2019)
50. Janssen EM, "CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death", Nature, 434, pp.88~93 (2005)
51. Fuse S, "Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1", J Immunol, 182, pp.4244~4254 (2009)
52. Townsend AR, "The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides", Cell, 44, pp.959~968 (1986)
53. Zhou X, "In vivo priming of cytotoxic T lymphocyte responses in relation to in vitro up-regulation of major histocompatibility complex class I molecules by short synthetic peptides", Eur J Immunol, 22, pp.3085~3090 (1992)
54. Crowe SR, "Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge", J Immunol, 174, pp.696~701 (2005)
55. Mbow ML, "New adjuvants for human vaccines", Curr Opin Immunol, 22, pp.411~416 (2010)
56. MacLeod MK, "Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells", Proc Natl Acad Sci U S A, 108, pp.7914~7919 (2011)
57. Mascaraque A, "Glycodendropeptides stimulate dendritic cell maturation and T cell proliferation : a potential influenza A virus immunotherapy", MedChemComm, 6, pp.1755~1760 (2015)
58. van der Zande HJ, "The mannose receptor : from endocytic receptor and biomarker to regulator of(meta)inflammation", Front Immunol, 12, pp.765034~ (2021)
59. Zhang H, "Broadly protective CD8+ T cell immunity to highly conserved epitopes elicited by heat shock protein gp96-adjuvanted influenza monovalent split vaccine", J Virol, 95, pp.e00507-21~ (2021)
60. Singh-Jasuja H, "Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis", J Exp Med, 191, pp.1965~1974 (2000)
61. Ju Y, "Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine", Vaccine, 32, pp.2703~2711 (2014)
62. Restuccia A, "Tuning carbohydrate density enhances protein binding and inhibition by glycosylated β-sheet peptide nanofibers", Biomater Sci, 6, pp.2327~2335 (2018)
63. Si Y, "Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses", J Control Release, 282, pp.120~130 (2018)
64. Si Y, "Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses", Sci Adv, 6, pp.eaba0995~ (2020)
65. Tate MD, "Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition", Sci Rep, 6, pp.27912~ (2016)
66. Belz GT, "Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses", J Immunol, 166, pp.4627~4633 (2001)
67. Zhong W, "Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire", J Biol Chem, 278, pp.45135~45144 (2003)
68. Arrieta-Bolaños E, "An HLA map of the world : a comparison of HLA frequencies in 200 worldwide populations reveals diverse patterns for class I and class II", Front Genet, 14, pp.866407~ (2023)
69. Valkenburg SA, "Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses", Proc Natl Acad Sci U S A, 113, pp.4440~4445 (2016)
70. Gianfrani C, "Human memory CTL response specific for influenza A virus is broad and multispecific", Hum Immunol, 61, pp.438~452 (2000)
71. Choo JA, "The immunodominant influenza A virus M158-66 cytotoxic T lymphocyte epitope exhibits degenerate class I major histocompatibility complex restriction in humans", J Virol, 88, pp.10613~10623 (2014)
72. Aktas E, "Relationship between CD107a expression and cytotoxic activity", Cell Immunol, 254, pp.149~154 (2009)
73. Koutsakos M, "Human CD8+ T cell cross-reactivity across influenza A, B and C viruses", Nat Immunol, 20, pp.613~625 (2019)
74. Budimir N, "Critical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine", PLoS One, 8, pp.e63163~ (2013)
75. Soema PC, "Whole-inactivated influenza virus is a potent adjuvant for influenza peptides containing CD8+ T cell epitopes", Front Immunol, 9, pp.525~ (2018)
76. Grant E, "Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses", Immunol Cell Biol, 91, pp.184~194 (2013)
77. van de Sandt CE, "Challenging immunodominance of influenza-specific CD8+ T cell responses restricted by the risk-associated HLA-A*68 : 01 allomorph", Nat Commun, 10, pp.5579~ (2019)
78. DiBrino M, "HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs", J Immunol, 151, pp.5930~5935 (1993)
79. Bolze A, "HLA-A*03 : 01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination", HGG Adv, 3, pp.100084~ (2022)
80. Solberg OD, "Balancing selection and heterogeneity across the classical human leukocyte antigen loci : a meta-analytic review of 497 population studies", Hum Immunol, 69, pp.443~464 (2008)
81. Quiñones-Parra S, "Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities", Proc Natl Acad Sci U S A, 111, pp.1049~1054 (2014)
82. Nguyen AT, "Homologous peptides derived from influenza A, B and C viruses induce variable CD8+ T cell responses with cross-reactive potential", Clin Transl Immunology, 11, pp.e1422~ (2022)
83. Grant EJ, "Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans", Nat Commun, 9, pp.5427~ (2018)
84. Rimmelzwaan GF, "Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes", Virus Res, 103, pp.97~100 (2004)
85. Muraduzzaman AK, "Understanding the role of HLA class I molecules in the immune response to influenza infection and rational design of a peptide-based vaccine", Viruses, 14, pp.2578~ (2022)
86. Sant S, "HLA-B*27 : 05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells", PLoS Pathog, 16, pp.e1008714~ (2020)
87. Rosendahl Huber SK, "Chemical modification of influenza CD8+ T-cell epitopes enhances their immunogenicity regardless of immunodominance", PLoS One, 11, pp.e0156462~ (2016)
88. Keskin DB, "Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity", Proc Natl Acad Sci U S A, 112, pp.2151~2156 (2015)
89. Chandele A, "Characterization of human CD8 T cell responses in dengue virus-infected patients from India", J Virol, 90, pp.11259~11278 (2016)
90. Hensen L, "CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24 : 02 allomorph", Nat Commun, 12, pp.2931~ (2021)
91. Alexander J, "Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus", Hum Immunol, 71, pp.468~474 (2010)
92. Liu J, "Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals", J Virol, 86, pp.13281~13294 (2012)
93. Kim SH, "Efficient anti-tumor immunotherapy using tumor epitope-coated biodegradable nanoparticles combined with polyinosinic-polycytidylic acid and an anti-PD1 monoclonal antibody", Immune Netw, 22, pp.e42~ (2022)
94. Slingluff CL Jr, "The present and future of peptide vaccines for cancer : single or multiple, long or short, alone or in combination?", Cancer J, 17, pp.343~350 (2011)
95. Heng WT, "Validation of multi-epitope peptides encapsulated in PLGA nanoparticles against influenza A virus", Pharm Res, 40, pp.1999~2025 (2023)
96. Lin PH, "Robust induction of TRMs by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses", Mol Ther Methods Clin Dev, 21, pp.299~314 (2021)
97. Khalaj-Hedayati A, "Nanoparticles in influenza subunit vaccine development : Immunogenicity enhancement", Influenza Other Respi Viruses, 14, pp.92~101 (2020)
98. Kim SH, "Induction of peptide-specific CTL activity and inhibition of tumor growth following immunization with nanoparticles coated with tumor peptide-MHC-I complexes", Immune Netw, 21, pp.e44~ (2021)
99. Lanfermeijer J, "Modified influenza M158-66 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge", NPJ Vaccines, 8, pp.116~ (2023)
100. Habel JR, "HLA-A*11 : 01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people", PLoS Pathog, 18, pp.e1010337~ (2022)

관련 논문AI추천